Genetics of Parkinson disease and other movement disorders

Current Opinion in Neurology

Volumn 25, Issue 4, 2012, Pages 466-474

  Kumar, Kishore R ^a,b   Lohmann, Katja ^a   Klein, Christine ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Genetics; Genome wide association studies; Glucocerebrosidase; Parkinson's disease; VPS35

Indexed keywords

GLUCOSYLCERAMIDASE;

BASAL GANGLION; DYSKINESIA; DYSTONIA; EIF4G1 GENE; ESSENTIAL TREMOR; GAUCHER DISEASE; GENE; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENOME ANALYSIS; HUMAN; INFANTILE SPASM; PARKINSON DISEASE; PAROXYSMAL KINESIGENIC DYSKINESIA; PATHOGENESIS; PRRT2 GENE; RESTLESS LEGS SYNDROME; REVIEW; SLC20A2 GENE; VPS35 GENE;

EID: 84863643572     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283547627     Document Type: Review

References (63)

1. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009; 461:272-276.
2. Vilarino-Guell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89:162-167.
3. Zimprich A, Benet-Pages A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89:168-175.
4. Guella I, Solda G, Cilia R, et al. The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Mov Disord 2012. doi:10.1002/mds.24927. [Epub ahead of print]
5. Sheerin UM, Charlesworth G, Bras J, et al. Screening for VPS35 mutations in Parkinson's disease. Neurobiol Aging 2012; 33:838.
6. Kumar KR, Weißbach A, Heldmann M, et al. Frequency of the D620N mutation in VPS35 in Parkinson disease,Archives of Neurology,Vol.69,Iss.10,Pages 1360 - 1364,2012
7. Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011; 89:398-406.
8. Wang C, Li Y, Shi L, et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet 2012; 44:254-256.
9. Shojaee S, Sina F, Banihosseini SS, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet 2008; 82:1375-1384.
10. Deng H, Liang H, Jankovic J. The FBXO7 gene in parkinsonian-pyramidal syndrome. Arch Neurol (in press).
11. Marras C, Lohmann K, Lang A, Klein C. Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. Neurology 2012; 78:1016-1024.
12. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41:1308-1312.
13. Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011; 7:e1002141.
14. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41:1303-1307.
15. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010; 74:97-109.
16. Saad M, Lesage S, Saint-Pierre A, et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet 2011; 20:615-627.
17. Liu X, Cheng R, Verbitsky M, et al. Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med Genet 2011; 12:104.
18. Spencer CC, Plagnol V, Strange A, et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 2011; 20:345-353.
19. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010; 42:781-785.
20. Plagnol V, Nalls MA, Bras JM, et al. A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 2011; 7:e1002142.
21. Lill CM, Roehr JT, McQueen MB, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PD gene database. PLoS Genet 2012; 8:e1002548.
22. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377:641-649.
23. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005; 76:672-680. (Pubitemid 40432174)
24. Tan EK. Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Ann Acad Med Singapore 2006; 35:840-842.
25. Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol 2011; 10:898-908.
26. Klein C, Ziegler A. From GWAS to clinical utility in Parkinson's disease. Lancet 2011; 377:613-614.
27. Wickremaratchi MM, Perera D, O'Loghlen C, et al. Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 2009; 80:805-807.
28. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a casecontrol study. Lancet Neurol 2008; 7:583-590.
29. Gan-Or Z, Bar-Shira A, Mirelman A, et al. The age at motor symptoms onset in LRRK2-associated Parkinson's disease is affected by a variation in the MAPT locus: a possible interaction. J Mol Neurosci 2012; 46:541-544.
30. Marras C, Schuele B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011; 77:325-333.
31. Saunders-Pullman R, Stanley K, Wang C, et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 2011; 77:319-324.
32. Mirelman A, Gurevich T, Giladi N, et al. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011; 69:193-197.
33. Lesage S, Condroyer C, Hecham N, et al. Mutations in the glucocerebrosidase gene confer a risk for Parkinson disease in North Africa. Neurology 2011; 76:301-303.
34. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD. Neurology 2012. [Epub ahead of print]
35. Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78:417-420.
36. Devine MJ, Ryten M, Vodicka P, et al. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2011; 2:440.
37. Seibler P, Graziotto J, Jeong H, et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 2011; 31:5970-5976.
38. Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011; 8:267-280.
39. Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I, et al. Diseasespecific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 2012. doi:10.1002/emmm.201200215. [Epub ahead of print]
40. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146:37-52.
41. Cookson MR. A feedforward loop links Gaucher and Parkinson's diseases? Cell 2011; 146:9-11.
42. Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol 2012; 8:203-213.
43. Chen WJ, Lin Y, Xiong ZQ, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet 2011; 43:1252-1255.
44. Li J, Zhu X, Wang X, et al. Targeted genomic sequencing identifies PRRT2 mutations as a cause of paroxysmal kinesigenic choreoathetosis. J Med Genet 2012; 49:76-78.
45. Wang JL, Cao L, Li XH, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain 2011; 134:3493-3501.
46. Lee HY, Huang Y, Bruneau N, et al. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Reports 2011; 1:2-12.
47. Heron SE, Grinton BE, Kivity S, et al. PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. Am J Hum Genet 2012; 90:152-160.
48. Ono S, Yoshiura KI, Kinoshita A, et al. Mutations in PRRT2 responsible for paroxysmal kinesigenic dyskinesias also cause benign familial infantile convulsions. J Hum Genet 2012. doi:10.1038/jhg.2012.23. [Epub ahead of print]
49. Schmidt A, Kumar KR, Redyk K, et al. Two faces of the same coin: Benign familial infantile seizures and paroxysmal kinesigenic dyskinesia. Arch Neurol (in press).
50. Stefansson H, Steinberg S, Petursson H, et al. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet 2009; 41:277-279.
51. Jimenez-Jimenez FJ, Garcia-Martin E, Lorenzo-Betancor O, et al. LINGO1 and risk for essential tremor: Results of a meta-analysis of rs9652490 and rs11856808. J Neurol Sci 2012. [Epub ahead of print]
52. Jasinska-Myga B, Wider C. Genetics of essential tremor. Parkinsonism Relat Disord 2012; 18:S138-S139.
53. Thier S, Lorenz D, Nothnagel M, et al. Polymorphism in the SLC1A2 gene are associated with essential tremor. Neurology (in press).
54. Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008; 40:946-948.
55. Winkelmann J, Schormair B, Lichtner P, et al.Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007; 39:1000-1006. (Pubitemid 47185185)
56. Kemlink D, Polo O, Frauscher B, et al. Replication of restless legs syndrome loci in three European populations. J Med Genet 2009; 46:315-318.
57. Yang Q, Li L, Chen Q, et al. Association studies of variants in MEIS1, BTBD9, and MAP2K5/SKOR1 with restless legs syndrome in a US population. Sleep Med 2011; 12:800-804.
58. Winkelmann J, Czamara D, Schormair B, et al. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet 2011; 7:e1002171.
59. Xiong L, Catoire H, Dion P, et al. MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet 2009; 18:1065-1074.
60. Catoire H, Dion PA, Xiong L, et al. Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis. Ann Neurol 2011; 70:170-175.
61. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012; 46:1-18.
62. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461:747-753.
63. Brockmann K, Groger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011; 26:2335-2342.